Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At least 3 episodes of urinary incontinence over a 3-day period
History of Multiple Sclerosis (MS)
Urinary incontinence not adequately controlled by anticholinergic medication
You may not be if
Current use of intermittent catheter or indwelling catheter to manage urinary incontinence
Previous or current botulinum toxin therapy of any serotype for any urological condition
Previous or current botulinum toxin therapy of any serotype for any non-urological condition within the last 12 weeks
Diagnosis of myasthenia gravis, Eaton-Lambert Syndrome, or Amyotrophic Lateral Sclerosis
Clareo Health | Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
